Gland Pharma FY25 Annual Earnings Summary

Cenexi is still a few quarters away from a complete turnaround; Q2 will be impacted by extended summer shutdown.

Cenexi's path to profitability may be delayed if new capacity ramp-up or commercial production timelines slip, or if lyophilizer issues recur.

Unannounced ANSM inspection at Fontenay caused production loss and corrective measures, pushing EBITDA breakeven to Q3 FY26. Further regulatory actions could delay recovery.

Cenexi's performance has been below expectations, with losses persisting due to remediation activities and equipment breakdowns. Achieving positive EBITDA by Q3 FY26 is uncertain.

U.S. market remains crowded; low-margin GPO contract and milestone income volatility could pressure margins.

Discussions for a strategic biologics collaboration are early-stage; may require significant investment with uncertain timeline.

Fosun sold a large stake in the quarter; management has no visibility on future share sales, which could impact sentiment.

U.S. revenue has been flat for three quarters despite multiple launches; growth may not materialize as expected if new contracts or Saudi offtake are delayed.

Cenexi gross margin fell sharply to 69% due to product mix; may not normalize quickly if site-level issues persist.

Base business revenue declined 8% YoY due to volume degrowth in key products like Enoxaparin. Recovery depends on timing of shipments and new product ramp-up.

The Saudi tender shipment was pushed out by a quarter, impacting Q3 revenue. Further delays could affect near-term ROW growth.

Chinese players control 50-60% of Heparin API supply. While US tariffs may benefit Gland, raw material dependence on China remains a risk.